GLP Watchdog

altRX vs MEDVi

altRX has an open FDA warning letter dated June 8, 2026. MEDVi has an open FDA warning letter dated February 20, 2026. On compounded semaglutide injection, altRX costs $1,320 less a year at standing rates: $89 a month against $199 a month at MEDVi.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

altRX / MEDVi

Featured pick (affiliate partner)

altRX logo

altRX

8.8/10

MEDVi logo

MEDVi

7.7/10

FDA warning letters
Pharmacy
  • RedRock Pharmacy503A
  • Health Warehousetype not stated
  • Precision Medicinetype not stated
  • and 1 more
Lowest standing price
$89/moCompounded semaglutide injection
$199/moCompounded semaglutide injection
States
All 50 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit altRX
Visit MEDVi

altRX is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. MEDVi pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, MEDVi 7.7). How we are paid

What the record shows

  1. 01

    altRX has an open FDA warning letter dated June 8, 2026. MEDVi has an open FDA warning letter dated February 20, 2026.

  2. 02

    altRX names four pharmacies. MEDVi names three pharmacies, all 503A.

  3. 03

    On compounded semaglutide injection, altRX costs $1,320 less a year at standing rates: $89 a month against $199 a month at MEDVi.

  4. 04

    Only altRX lists a price for compounded tirzepatide injection, brand-name semaglutide pen and brand-name tirzepatide pen.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

altRX

MEDVi

Compounded semaglutide injection

$89/moLower

$1,068 a year

$199/mo

$2,388 a year

Compounded tirzepatide injection

$149/mo

$1,788 a year

Not sold or not priced
Brand-name semaglutide pen

$1,149/mo

$13,788 a year

Not sold or not priced
Brand-name tirzepatide pen

$1,249/mo

$14,988 a year

Not sold or not priced
Price includes
Medication, clinician visits, shipping
Medication, clinician visits, shipping, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on the monthly plan; multi-month plans are prepaid and non-refundable
None; billed monthly
Refunds
All payments are final and non-refundable, except a partial refund if you are medically disqualified
Full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed
Early-exit fee
Not stated
None stated

Read off each seller’s own pages. altRX: September 28, 2026. MEDVi: October 25, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for altRX

8.8/10
Featured pick (affiliate partner)
  • $1,320 a year less on compounded semaglutide injection
  • Sells compounded tirzepatide injection and brand-name semaglutide pen, which MEDVi does not price
  • Open FDA warning letter, June 8, 2026
Visit altRX

The case for MEDVi

7.7/10

The record gives MEDVi no edge on this pair.

  • Open FDA warning letter, February 20, 2026
Visit MEDVi

Scores

altRX 8.8 · MEDVi 7.7 out of 10. Six weighted parts.

Value25%

10.0A
vs
B
5.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
6.0

Accessibility10%

10.0A
vs
B
10.0

Support10%

7.0A
vs
B
8.5

The score is the same formula for every seller. Payment does not enter it. Method

altRX vs MEDVi: questions

altRX has an open FDA warning letter dated June 8, 2026. MEDVi has an open FDA warning letter dated February 20, 2026. Letters are matched to a seller by company, domain and address, never by a similar name.
altRX names four pharmacies. MEDVi names three pharmacies, all 503A. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
altRX, by $1,320 a year at standing rates. altRX: $89 a month, about $1,068 a year. MEDVi: $199 a month, about $2,388 a year.
altRX states you can cancel at any time; refunds: all payments are final and non-refundable, except a partial refund if you are medically disqualified. MEDVi states you can cancel at any time; refunds: full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed.
altRX is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. MEDVi pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, MEDVi 7.7).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks